In a report released yesterday, Tycho Peterson from Jefferies reiterated a Buy rating on Bruker (BRKR – Research Report), with a price target of $80.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tycho Peterson has given his Buy rating due to a combination of factors that indicate strong potential for Bruker’s future performance. The company’s recent fourth-quarter results showed core growth that slightly exceeded expectations, driven by solid performance in several key areas such as BioSpin, NANO, and CALID. Despite concerns around the NIH budget cuts, which constitute only a small fraction of their sales, Bruker continues to demonstrate resilience with an attractive margin runway and a steady backlog.
Furthermore, Bruker’s valuation remains appealing, with the potential for both numbers and valuation multiples to increase. The company’s strategic positioning in the semiconductor and AI sectors, alongside a positive outlook in biopharma recovery and other growing markets, supports this optimistic view. Additionally, Bruker’s guidance for adjusted operating margin expansion and core EPS growth reflects confidence in their operational improvements and market opportunities.
In another report released today, Barclays also maintained a Buy rating on the stock with a $60.00 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock.